Research Assistant Professor
CurrentLeading an interdisciplinary research team for the laboratory of W. Richard Burack, M.D., Ph.D, Director of Hematopathology, Director of Molecular Genetics, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center. Research goals include the development and validation of massively parallel (next generation) sequencing approaches to the diagnosis of hematopoietic malignancies, with special emphasis on lymphomas. We have developed a novel analytical pipeline for analysis of next generation sequencing data to identify and quantify tumor sub-populations, the key to aggressive transformation and chemo-resistance. This approach allows discernment of sub-populations at <0.5% levels and subsequent construction of tumor dendrograms, allowing a deeper characterization of tumor sub-population dynamics. Our goal is to determine if relative rates of mutation versus growth within sub-populations has prognostic value with regard to patient outcome and therapeutic responsiveness. In 2013 we received a highly competitive CTSI pilot award to expand these studies on Follicular Lymphoma clinical specimens towards data generation for grant applications. Additionally, we have developed a patent-pending assay for determining IGH sequence from CLL tumors for prognostic purposes. This assay is currently being validated for use by the Molecular Diagnostic Laboratory at URMC and has been successfully licensed to an outside molecular diagnostic company for clinical use. Current projects also include the development of a NGS B-cell clonality assay based on IGH sequence.